Nuchal translucency appears on ultrasound as a dark, anechoic space between the skin of the fetal neck and the soft tissues beneath it. It is a fleeting feature of normal development: between roughly 11 and 14 weeks of gestation, the lymphatic vessels of the neck gradually forge connections with the jugular venous system, and before those channels are fully open, a small amount of lymphatic fluid pools in the cervical region. In most fetuses, the accumulation drains away after week 14. But when the measured thickness exceeds 2.5 millimeters, clinicians treat it as a red flag for adverse outcomes. Increased nuchal translucency has been linked to a sweeping spectrum of problems, from chromosomal abnormalities and structural birth defects to single-gene syndromes such as Noonan syndrome, skeletal dysplasias, and an assortment of neurodevelopmental disorders. Until now, however, Pitt-Hopkins syndrome was nowhere on that list.

Pitt-Hopkins syndrome is a rare and devastating condition caused, in the overwhelming majority of cases, by mutations in TCF4, a gene that encodes transcription factor 4—a DNA-binding protein that switches other genes on and off during development. The disorder follows an autosomal dominant pattern, meaning a single faulty copy is enough to cause disease, and it announces itself after birth with profound intellectual disability, distinctive craniofacial abnormalities, characteristic facial features, and generalized low muscle tone. Some affected children develop epilepsy, myopia, and episodes of deep, rapid hyperventilation. Several hundred individuals worldwide have now received the diagnosis, carrying a wide range of TCF4 defects: missense and nonsense changes, small insertions and deletions that scramble the reading frame, larger structural rearrangements, and splicing variants. Crucially, because the syndrome is usually recognized in children rather than fetuses, increased nuchal translucency had never been reported in connection with it—until this case.

The story began in March 2023, when a woman who had undergone a frozen embryo transfer at Zhejiang Provincial People’s Hospital became pregnant with dichorionic diamniotic twins, each developing in a separate placenta and a separate amniotic sac. First-trimester ultrasound told two very different stories. Fetus A measured 1.9 millimeters of nuchal translucency, comfortably within the normal range, and showed no other prenatal abnormalities. Fetus B measured 3.5 millimeters, well past the 2.5-millimeter warning threshold. With no family history to guide them and both parents apparently healthy, the clinical team collected amniotic fluid from fetus B along with blood samples from both mother and father, then performed trio-based clinical exome sequencing to compare all three genomes at once. The study was approved by the hospital’s medical ethics committee, and the parents provided written informed consent.

Clinical exome sequencing is a targeted deep-sequencing strategy that homes in on the protein-coding regions of the genome—the fraction of DNA that harbors most known disease-causing variants—along with 20 base pairs of flanking intronic sequence on each side of every exon. In this case, the assay covered 7,099 clinically relevant human genes. The team fragmented and repaired fetal DNA, ligated sequencing adapters, captured the target regions with a clinical exome kit, and sequenced the libraries on an Illumina NextSeq 550DX platform, aligning the resulting reads to the human reference genome hg19 (GRCh37) with the Burrows-Wheeler Aligner. Candidate variants were then filtered against public databases including dbSNP, ExAC, HGMD, ClinVar, OMIM, and gnomAD. Copy-number analysis, performed both on the exome data and with a dedicated CNV-seq assay, came back clean, ruling out large duplications and deletions. What remained was a single striking finding: a heterozygous variant, c.1146+3A>T, lodged in intron 14 of the TCF4 gene (transcript NM_001083962.1)—present in the fetus and in neither parent. Sanger sequencing confirmed the call: the mutation had arisen de novo, in the fetus alone.

A single-letter change three base pairs into an intron might seem trivial, but in splicing, position is everything. The variant disrupts the donor splice site—the molecular signal that tells the cell’s splicing machinery where an exon ends and the intron begins. To prove the point, the researchers built a minigene assay. They amplified a 1,404-base-pair segment of the relevant TCF4 region from the fetus’s amniotic fluid DNA and, in parallel, from a normal control, then inserted each fragment into a pcMINI reporter plasmid using the restriction enzymes KpnI and NotI. The two constructs—one wild-type, one mutant—were introduced into HEK-293T kidney cells and HeLa cervical cancer cells with Lipofectamine 3000, and 48 hours later the cells’ RNA was extracted, reverse-transcribed, and read out. The difference was unmistakable. Cells receiving the wild-type construct produced a transcript with exon 14 neatly spliced into place. Cells receiving the mutant construct produced a shorter product in which exon 14 had been skipped entirely, stitched directly from the preceding exon to the following one.

The consequences cascade from there. Losing exon 14 deletes 77 nucleotides of coding sequence, shifting the reading frame and generating a premature stop codon in exon 15—a change annotated p.Gly358Lysfs*4. The result is a truncated TCF4 protein of just 360 amino acids, stripped of its C-terminal region, including the conserved basic helix–loop–helix domain the protein needs to grip DNA and dimerize with partner proteins. That domain, encoded across exons 9 through 19, is precisely the region where Pitt-Hopkins mutations do their worst damage, wrecking protein stability, DNA binding, and transcriptional activation. Applying the joint interpretation guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, the team classified the variant as pathogenic, stacking five independent lines of evidence: a different nucleotide substitution at the same donor splice site had already been reported as a de novo variant in a Pitt-Hopkins patient and judged likely pathogenic; the variant arose de novo with both parents confirmed as non-carriers; it is absent from the gnomAD population database; three separate splicing-prediction tools flagged the disruption of the highly conserved donor site of exon 14, a non-phase exon; and the minigene experiment delivered direct functional proof of exon skipping.

The case slots into a wider pattern that prenatal specialists have been assembling. In a cohort study of 503 twin pregnancies, increased nuchal translucency in at least one fetus was associated with a significantly higher risk of adverse outcomes than when both fetuses measured normally. More sobering still, among 1,658 fetuses with increased translucency followed through 1,309 live births, roughly one percent of infants still showed neurodevelopmental delay or abnormalities even after chromosomal abnormalities and pathogenic copy-number variants had been excluded—hinting that hidden single-nucleotide variants account for a stubborn residual risk. Recent reports have been closing that gap one gene at a time: a de novo SMAD4 variant in a fetus whose measurement reached 5.7 millimeters, later explained as multi-system Myhre syndrome, and compound heterozygous NUP107 variants in two fetuses with increased translucency who later showed renal anomalies and neurodevelopmental impairment. The new TCF4 finding extends that expanding map. Notably, a change at this very splice site, c.1146+3A>G, was documented in an affected child back in 2008, and across the nine previously reported patients carrying TCF4 splicing variants, every case displayed the core features of the syndrome: global developmental delay, severe language impairment, hypotonia, facial dysmorphism, and intellectual disability.

The discovery also underscores how far TCF4’s influence reaches beyond the developing brain. The gene is broadly expressed and participates in multiple developmental pathways; an entirely different TCF4 lesion—a CTG trinucleotide repeat expansion known as CTG18.1 lodged within one of its introns—causes Fuchs endothelial corneal dystrophy, a common cause of progressive vision loss. Many of Pitt-Hopkins’ apparently non-neurological features, including abnormal breathing patterns and constipation, may in fact reflect autonomic nervous system dysfunction rather than isolated defects of unrelated organs. And the syndrome’s presentation can be startlingly variable: one family carrying a missense change in exon 18 (c.1849G>A, resulting in p.Val617Ile) showed only mild, nonspecific neurodevelopmental impairment rather than the full classical picture. For clinicians and genetic counselors, the message is that TCF4-related disease is not a monolithic entity but a spectrum—one more reason any prenatal clue, however subtle, deserves attention.

The twins’ story did not end in the sequencing lab. When the team followed up during the children’s first and second years of life, fetus A—now a toddler—was healthy and developing normally, exactly as predicted. Fetus B, by contrast, showed widening of the brain’s lateral ventricles along with delayed growth and development, hallmark features of Pitt-Hopkins syndrome that strengthened the prenatal suspicion. Because the disorder typically unfolds across childhood, the researchers expect additional symptoms to emerge over time and plan close monitoring of the child. Taken together—the de novo occurrence of the variant, the minigene proof of exon 14 skipping, the truncated protein shorn of its DNA-binding domain, and the postnatal neurological signs—the evidence points firmly to c.1146+3A>T as a genuine, pathogenic Pitt-Hopkins mutation. And it elevates a routine ultrasound measurement into something far more consequential: a potential early intrauterine sign of TCF4-related disease. For any fetus with unexplained increased nuchal translucency, the researchers conclude, Pitt-Hopkins syndrome and related TCF4 disorders should now enter the differential diagnosis.

Researchers at The Hospital for Sick Children (SickKids) in Toronto have developed a machine-learning approach that could help resolve some of that uncertainty. The method converts blood-based epigenetic patterns into “tissue-agnostic” episignatures—molecular signals that can identify a genetic condition regardless of whether the DNA came from blood, amniotic fluid, placental tissue or another biological source. The advance could eventually make epigenetic testing more useful in prenatal medicine, where access to fetal tissues is limited and clinical decisions often must be made before birth.

The work focuses on epigenetics, the system of chemical modifications that regulates how genes operate without changing the underlying DNA sequence. One of the most important epigenetic mechanisms is DNA methylation, in which chemical groups attach to specific DNA bases and influence whether nearby genes are active or silent. Certain genetic disorders produce distinctive, disease-associated methylation patterns across the genome. These patterns, called episignatures, can act like molecular fingerprints, helping clinicians determine whether a genetic variant is likely to disrupt normal development.

The SickKids team, led by Clinical Geneticist and Senior Associate Scientist Rosanna Weksberg and Senior Research Associate Sanaa Choufani, has helped establish more than 60 episignatures. Many have already been clinically validated for diagnostic use. Traditionally, however, these signatures have been considered tissue-specific. A methylation pattern identified in blood might not be directly applicable to DNA extracted from prenatal samples, because different tissues undergo distinct developmental and regulatory processes. That limitation has prevented many families undergoing prenatal testing from benefiting from episignature-based analysis.

To test whether this barrier could be overcome, the researchers first generated a blood-derived episignature for Down syndrome, a condition caused in most cases by an extra copy of chromosome 21. The signature was built using samples from 266 people with Down syndrome. The team then used publicly available DNA methylation data from 850 individuals with and without the condition to train a machine-learning model. The dataset included six prenatal and postnatal tissue types, allowing the researchers to compare disease-associated methylation patterns across tissues with very different biological functions.

Rather than searching for a single methylation site, the model analyzed coordinated changes across numerous regions of the genome. Machine-learning algorithms can identify combinations of features that are difficult to recognize through manual inspection, including patterns that remain biologically meaningful even when their strength varies between tissues. In this case, the model was designed to preserve the core information of the blood-derived Down syndrome signature while adapting it to the molecular characteristics of other tissues.

The results demonstrated that the transformed signature accurately recognized the Down syndrome pattern in every tissue type tested. This finding suggests that a blood-derived episignature can be computationally converted into a broader diagnostic signal without losing its ability to distinguish affected and unaffected samples. The result does not mean that every genetic condition will produce a universal signature, but it provides proof that tissue-specificity—one of the major challenges in epigenetic diagnostics—may be reduced with carefully trained models and sufficiently diverse reference data.

The potential clinical impact is particularly important for prenatal diagnosis. Amniotic fluid and placental tissue may be available during pregnancy, but they are not equivalent to blood and can contain limited amounts of DNA. A tissue-agnostic episignature could allow clinicians to compare prenatal methylation data with established diagnostic patterns even when the original signature was discovered in postnatal blood. In practical terms, the approach could help interpret uncertain variants and provide families with more precise information at a time when uncertainty can have profound emotional and medical consequences.

The researchers also believe the strategy could eventually expand testing beyond conventional blood samples. Saliva and oral swabs, which are easier and less invasive to collect, may become useful sources of DNA if their molecular signals can be reliably connected to disease-associated episignatures. Such applications would require extensive validation across larger and more diverse populations, as well as careful assessment of false-positive and false-negative results. Machine-learning systems must also be tested in real clinical settings to ensure that their predictions remain reliable when samples vary in quality, ancestry, developmental stage and medical history.

The study, published in The American Journal of Human Genetics, represents an early but significant step toward more flexible epigenetic diagnostics. By combining genome-scale methylation analysis with machine learning, the SickKids team has shown that information discovered in one tissue can potentially be translated to others. The researchers say the long-term goal is to shorten the diagnostic odyssey experienced by many children and families affected by rare genetic disorders, while giving clinicians clearer evidence for interpreting uncertain variants. Supported by the Canadian Institutes of Health Research, the work could help advance a more individualized approach to prenatal and pediatric care, in which molecular data are used not only to diagnose disease but also to guide families through some of medicine’s most difficult decisions.

Subject of Research: Tissue-agnostic epigenetic signatures and machine-learning-assisted interpretation of genetic variants for prenatal diagnosis.

Web References: The American Journal of Human Genetics study; EpigenCentral; Rosanna Weksberg; SickKids Genetics & Genome Biology.

References: American Journal of Human Genetics; The Hospital for Sick Children; Canadian Institutes of Health Research.

Image Credits: The Hospital for Sick Children.

Keywords

Prenatal genetic testing, variants of uncertain significance, episignatures, DNA methylation, epigenetics, tissue-agnostic diagnostics, machine learning, Down syndrome, prenatal medicine, genetic disorders, medical genetics, SickKids

The scientific advancements enabling this leap come from deepening knowledge of the human genome, fetal development, and the intricate molecular pathways disrupted by pathogenic mutations. Neurogenetic diseases, caused by mutations in genes critical for brain development and function, often manifest catastrophic symptoms shortly after birth. Traditional postnatal interventions have met with limited success, mostly mitigating symptoms rather than halting or reversing disease progression. Administering precise treatments during the fetal period could arrest the pathological cascade at its inception, improving survival and quality of life.

Technologically, the confluence of high-resolution fetal imaging, non-invasive prenatal genetic testing, and RNA- or gene-based therapeutics has made in utero interventions plausible. Techniques such as amniotic fluid sampling and cell-free fetal DNA analysis via maternal blood enable early, definitive diagnosis without risking the fetus through invasive biopsy. Precise genotypic characterization facilitates identification of the molecular defect, guiding the design of targeted therapies to compensate for or correct the aberrant gene function within the delicate neural environment.

One of the most remarkable technical challenges is delivering these therapies safely and effectively in the uterine environment, which presents formidable biological barriers and demands minimal disruption to the dynamic developmental processes occurring inside the womb. Viral vectors engineered to cross the placental barrier or be administered directly to the fetal brain via minimally invasive ultrasound-guided injections are at the forefront of current research, aiming to achieve efficient gene editing or decoy RNA delivery with maximal specificity and minimal immunogenicity.

From a clinical standpoint, early intervention holds undeniable promise. Identifying fetuses with mutations that predict severe neuropathology and intervening before irreversible brain damage accumulates could prevent the onset of debilitating symptoms such as seizures, developmental delay, and neuromuscular impairment. However, this hopeful vision must be balanced with rigorous clinical trial designs to validate efficacy, optimize dosing, and monitor long-term outcomes, including neurodevelopmental milestones and potential off-target effects.

Ethically, the introduction of in utero precision medicine raises multifaceted considerations. The decision to initiate fetal therapy must navigate parental autonomy, informed consent, and the evolving capacity of the fetus as a patient. Weighing potential risks to both mother and fetus against the likelihood of therapeutic benefits demands robust ethical frameworks and transparent communication. Additionally, equitable access and the implications of potentially altering germline cells warrant ongoing societal and regulatory discourse to avoid exacerbating health disparities or unintended hereditary consequences.

The translational path from bench to bedside for these therapies requires cross-disciplinary collaboration—from molecular biologists deciphering neurogenetic pathways, to clinicians specializing in maternal-fetal medicine, pediatric neurology, and ethics experts ensuring responsible implementation. Regulatory agencies are simultaneously adapting guidelines to accommodate these novel prenatal interventions, balancing innovation with safety and ethical integrity.

Recent case studies in animal models have demonstrated proof-of-concept success where gene editing tools like CRISPR-Cas9 or antisense oligonucleotides, delivered during gestation, ameliorated phenotypes associated with inherited neurodegenerative conditions. These preclinical findings fuel optimism but also highlight the necessity for exhaustive safety assessments, particularly concerning unintended genomic alterations and the timing of intervention relative to the critical windows of neurodevelopment.

In parallel, advances in bioinformatics and single-cell transcriptomics provide deeper insight into fetal brain cellular heterogeneity and temporal gene expression, enabling refinement of therapeutic targets and delivery timing with unparalleled precision. This molecular granularity permits custom-tailoring of interventions to individual fetal disease profiles rather than one-size-fits-all approaches.

Safety monitoring frameworks for in utero interventions are evolving to include not only immediate perinatal outcomes but also comprehensive neurodevelopmental follow-up extending into childhood and adolescence. The complex interplay between the therapy, fetal immune environment, and developmental milieu mandates vigilant surveillance to capture subtle phenotypic changes that could emerge from off-target effects or immune responses.

From a societal perspective, the prospect of preventing lifelong disability through prenatal intervention resonates strongly with patients, families, and advocacy groups. However, it simultaneously provokes critical discussion about the limits of intervention, potential for ‘designer babies,’ and the societal responsibilities accompanying the power to edit human genomes before birth.

Financial considerations also play a role in shaping the landscape of in utero precision medicine. The high cost of developing and delivering advanced gene therapies, coupled with the scarcity of expertise and specialized facilities, may limit widespread adoption initially. This underscores the imperative to integrate cost-effectiveness analyses and health policy strategies early in the translational process to ensure accessibility beyond experimental settings.

Importantly, the field is poised to capitalize on synergistic advances in stem cell technology, enabling the generation of patient-specific fetal models for drug testing and therapy optimization. These in vitro platforms could accelerate therapeutic development by reducing reliance on animal models and better predicting human outcomes.

In summary, in utero precision medicine heralds a new epoch in treating severe early-onset neurogenetic diseases, blending cutting-edge genomic medicine, fetal diagnostics, and ethical deliberation to chart a path from theoretical promise to tangible clinical reality. As the scientific community navigates this frontier, the collective commitment to safety, efficacy, and equity will determine whether these transformative interventions can be brought from the laboratory to the lives of patients in need.

Subject of Research: In utero precision medicine for severe, early-onset neurogenetic diseases.

Article Title: In utero precision medicine for severe, early-onset neurogenetic disease: scientific, clinical and ethical considerations.

Article References:
Borges, B., Brown, J.E.H. & Gano, D. In utero precision medicine for severe, early-onset neurogenetic disease: scientific, clinical and ethical considerations. Pediatr Res (2025). https://doi.org/10.1038/s41390-025-04487-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-025-04487-y